John Bisi

4.3k total citations · 1 hit paper
35 papers, 2.9k citations indexed

About

John Bisi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, John Bisi has authored 35 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 16 papers in Molecular Biology. Recurrent topics in John Bisi's work include Advanced Breast Cancer Therapies (16 papers), Cancer-related Molecular Pathways (14 papers) and Lung Cancer Research Studies (7 papers). John Bisi is often cited by papers focused on Advanced Breast Cancer Therapies (16 papers), Cancer-related Molecular Pathways (14 papers) and Lung Cancer Research Studies (7 papers). John Bisi collaborates with scholars based in United States, United Kingdom and Australia. John Bisi's co-authors include Jay C. Strum, Lee E. Babiss, Patrick J. Roberts, Bryan Goodwin, Michele A. Bonham, Stephen A. Thomson, Jeffery C. Hanvey, Stewart A. Noble, C. Fred Hassman and Nancy J. Peffer and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

John Bisi

33 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis

2003 563 citations John Bisi, Bryan Goodwin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Bisi United States	21	1.8k	1.2k	486	359	271	35	2.9k
Igor Astsaturov United States	32	1.2k 0.7×	1.1k 1.0×	496 1.0×	411 1.1×	255 0.9×	97	2.7k
Kazutsugu Uematsu Japan	22	1.9k 1.1×	1.2k 1.0×	673 1.4×	142 0.4×	214 0.8×	56	2.9k
John F. Lyons United States	32	2.7k 1.5×	1.3k 1.1×	454 0.9×	251 0.7×	276 1.0×	81	4.3k
Sylvie Gazzéri France	36	2.5k 1.4×	1.6k 1.3×	581 1.2×	175 0.5×	358 1.3×	63	3.5k
Sun W. Tam United States	14	2.2k 1.2×	2.1k 1.8×	246 0.5×	199 0.6×	188 0.7×	17	3.2k
Geoffrey W. Krystal United States	32	1.9k 1.0×	970 0.8×	404 0.8×	199 0.6×	328 1.2×	50	3.2k
Frank Hilberg Austria	28	2.0k 1.1×	1.1k 1.0×	1.2k 2.5×	272 0.8×	197 0.7×	57	4.0k
Torben F. Ørntoft Denmark	13	2.5k 1.4×	1.5k 1.3×	269 0.6×	504 1.4×	127 0.5×	20	3.6k
Lynn Cawkwell United Kingdom	30	1.3k 0.7×	890 0.7×	404 0.8×	339 0.9×	99 0.4×	90	2.6k
Chouhei Sakakura Japan	27	1.2k 0.7×	723 0.6×	458 0.9×	638 1.8×	156 0.6×	104	2.4k

Countries citing papers authored by John Bisi

Since Specialization

Citations

This map shows the geographic impact of John Bisi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Bisi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Bisi more than expected).

Fields of papers citing papers by John Bisi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Bisi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Bisi. The network helps show where John Bisi may publish in the future.

Co-authorship network of co-authors of John Bisi

This figure shows the co-authorship network connecting the top 25 collaborators of John Bisi. A scholar is included among the top collaborators of John Bisi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Bisi. John Bisi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kumarasamy, Vishnu, Michelle Roti, John Bisi, et al.. (2025). Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle. Nature Communications. 16(1). 1476–1476. 8 indexed citations

Ahn, Antonio, Michael Taylor, Keefe T. Chan, et al.. (2023). INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors. Cancer Discovery. 14(3). 446–467. 62 indexed citations

Wardell, Suzanne E., Robert Baldi, Christina Chao, et al.. (2020). G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Research and Treatment. 180(3). 635–646. 37 indexed citations

Tadema, Henko, William A. Wargin, Shenghui He, et al.. (2020). Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. UNC Libraries. 3 indexed citations

Bisi, John, et al.. (2019). Abstract 4414: Inhibition of CDK2 overcomes primary and acquired resistance to CDK4/6 inhibitors. Cancer Research. 79(13_Supplement). 4414–4414. 7 indexed citations

Guijarro, Irene, Alissa Poteete, Renata Ferrarotto, et al.. (2017). P2.03a-048 The CDK4/6 Inhibitor G1T28 Protects Immune Cells from Cisplatin-Induced Toxicity in vivo and Inhibits SCLC Tumor Growth. Journal of Thoracic Oncology. 12(1). S918–S918. 1 indexed citations

Bisi, John, Jessica A. Sorrentino, Patrick J. Roberts, Francis X. Tavares, & Jay C. Strum. (2016). Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Molecular Cancer Therapeutics. 15(5). 783–793. 90 indexed citations

Tiessen, Renger G., Patrick J. Roberts, Jessica A. Sorrentino, et al.. (2015). First-in-human Phase 1 safety, PK, and PD study of the CDK4/6 inhibitor G1T28.. Journal of Clinical Oncology. 33(15_suppl). 2527–2527. 5 indexed citations

Roberts, Patrick J., Jessica A. Sorrentino, Henko Tadema, et al.. (2015). Evaluation of targeted bone marrow arrest by G1T28, a CDK4/6 inhibitor in clinical development to reduce chemotherapy-induced myelosuppression.. Journal of Clinical Oncology. 33(15_suppl). 2529–2529. 3 indexed citations

10.

Roberts, Patrick J., John Bisi, Jay C. Strum, et al.. (2012). Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy. JNCI Journal of the National Cancer Institute. 104(6). 476–487. 215 indexed citations

11.

Nofziger, Charity, Kathleen K. Brown, Chari D. Smith, et al.. (2009). PPARγ agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line. American Journal of Physiology-Renal Physiology. 297(1). F55–F62. 35 indexed citations

12.

Xia, Wenle, John Bisi, Jay C. Strum, et al.. (2006). Regulation of Survivin by ErbB2 Signaling: Therapeutic Implications for ErbB2-Overexpressing Breast Cancers. Cancer Research. 66(3). 1640–1647. 128 indexed citations

13.

Parton, Laura E., Frédérique Diraison, Sujoy Ghosh, et al.. (2004). Impact of PPARγ overexpression and activation on pancreatic islet gene expression profile analyzed with oligonucleotide microarrays. American Journal of Physiology-Endocrinology and Metabolism. 287(3). E390–E404. 30 indexed citations

14.

Delerive, Philippe, Cristin M. Galardi, John Bisi, Edwige Nicodème, & Bryan Goodwin. (2004). Identification of Liver Receptor Homolog-1 as a Novel Regulator of Apolipoprotein AI Gene Transcription. Molecular Endocrinology. 18(10). 2378–2387. 78 indexed citations

15.

Yang, Shutong, Christin S. Kuo, John Bisi, & Myung K. Kim. (2002). PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nature Cell Biology. 4(11). 865–870. 187 indexed citations

16.

Bonham, Michele A., Stephen Brown, Ann L. Boyd, et al.. (1995). An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucleic Acids Research. 23(7). 1197–1203. 134 indexed citations

17.

Noble, Stewart A., Michele A. Bonham, John Bisi, et al.. (1995). Impact of biophysical parameters on the biological assessment of peptide nucleic acids, antisense inhibitors of gene expression. Drug Development Research. 34(2). 184–195. 22 indexed citations

18.

Peffer, Nancy J., Jeffery C. Hanvey, John Bisi, et al.. (1993). Strand-invasion of duplex DNA by peptide nucleic acid oligomers.. Proceedings of the National Academy of Sciences. 90(22). 10648–10652. 141 indexed citations

19.

Hanvey, Jeffery C., Nancy J. Peffer, John Bisi, et al.. (1992). Antisense and Antigene Properties of Peptide Nucleic Acids. Science. 258(5087). 1481–1485. 440 indexed citations

20.

Welch, Danny R., John Bisi, Bonnie E. Miller, et al.. (1991). Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. International Journal of Cancer. 47(2). 227–237. 177 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact